MedTrace Logo

A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants

NCT07678463 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-07-15

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and tolerability of QX-4533 following oral administration of single and multiple ascending doses in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

QX-4533

QX-4533 tablets

DRUG

Placebo

QX-4533 matched-placebo tablets

Sponsors & Collaborators

  • QuantX Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Gregory Bell, MD · Leader of Clinical Development Department

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-10
Primary Completion
2026-12-25
Completion
2027-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07678463 on ClinicalTrials.gov